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Background: High systemic estrogen levels contribute to breast cancer risk for postmenopausal women, whereas
low levels contribute to osteoporosis risk. Except for obesity, determinants of non-ovarian systemic estrogen levels
are undefined. We sought to identify members and functions of the intestinal microbial community associated with
estrogen levels via enterohepatic recirculation.
Methods: Fifty-one epidemiologists at the National Institutes of Health, including 25 men, 7 postmenopausal
women, and 19 premenopausal women, provided urine and aliquots of feces, using methods proven to yield
accurate and reproducible results. Estradiol, estrone, 13 estrogen metabolites (EM), and their sum (total estrogens)
were quantified in urine and feces by liquid chromatography/tandem mass spectrometry. In feces, β-glucuronidase
and β-glucosidase activities were determined by realtime kinetics, and microbiome diversity and taxonomy were
estimated by pyrosequencing 16S rRNA amplicons. Pearson correlations were computed for each loge estrogen
level, loge enzymatic activity level, and microbiome alpha diversity estimate. For the 55 taxa with mean relative
abundance of at least 0.1%, ordinal levels were created [zero, low (below median of detected sequences), high] and
compared to loge estrogens, β-glucuronidase and β-glucosidase enzymatic activity levels by linear regression.
Significance was based on two-sided tests with α=0.05.
Results: In men and postmenopausal women, levels of total urinary estrogens (as well as most individual EM) were
very strongly and directly associated with all measures of fecal microbiome richness and alpha diversity (R≥0.50,
P≤0.003). These non-ovarian systemic estrogens also were strongly and significantly associated with fecal Clostridia
taxa, including non-Clostridiales and three genera in the Ruminococcaceae family (R=0.57−0.70, P=0.03−0.002).
Estrone, but not other EM, in urine correlated significantly with functional activity of fecal β-glucuronidase (R=0.36,
P=0.04). In contrast, fecal β-glucuronidase correlated inversely with fecal total estrogens, both conjugated and
deconjugated (R≤-0.47, P≤0.01). Premenopausal female estrogen levels, which were collected across menstrual
cycles and thus highly variable, were completely unrelated to fecal microbiome and enzyme parameters (P≥0.6).
Conclusions: Intestinal microbial richness and functions, including but not limited to β-glucuronidase, influence
levels of non-ovarian estrogens via enterohepatic circulation. Thus, the gut microbial community likely affects the
risk for estrogen-related conditions in older adults. Understanding how Clostridia taxa relate to systemic estrogens
may identify targets for interventions.
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Breast cancer risk is increased among postmenopausal
women who have high levels of endogenous estrogens
[1-3]. Conversely, high estrogen levels are associated with
a reduced risk of osteoporosis and hip fracture in both
postmenopausal women and elderly men [4-6]. Metabolism
of estrogens occurs predominantly in the liver, including
hydroxylation and conjugation [7]. Conjugated estrogens
are excreted in the bile and ultimately pass into the distal
gut, where they are variably deconjugated. These liberated,
biologically active hormones are reabsorbed through the
mucosa and enter the circulation through the portal vein
[8]. A working hypothesis is that this enterohepatic recircu-
lation affects the half-life and systemic levels of estrogens in
men and postmenopausal women, and perhaps during the
luteal phase in premenopausal women [9-11]. Except for
obesity [3,12], determinants of non-ovarian estrogen levels
remain enigmatic [13,14]. The diversity of the gut micro-
biota, which is inversely associated with body mass index
(BMI) and obesity [15,16], could influence systemic estro-
gen levels through enzymatic and other pathways [11].
To characterize the distal gut microbiota and its associa-
tions with phenotypes, we developed methods that pro-
vide highly reproducible, DNA pyrosequencing-based
classification of the diversity and major phyla of the fecal
microbiome [16], functional activities of two fecal micro-
bial deconjugating enzymes (β-glucuronidase and β-gluco-
sidase) [17], and associations of these with each other and
with broad characteristics of human volunteers [16-18].
Herein, using liquid chromatography/tandem mass spec-
trometry (LC-MS/MS) for highly sensitive and reprodu-
cible detection of the parent estrogens (estrone and
estradiol) and 13 estrogen metabolites (EM) [19], we
investigated the following: 1) whether systemic estrogen
levels were associated with fecal microbial diversity or par-
ticular taxa; 2) whether systemic estrogen levels were asso-
ciated with fecal β-glucuronidase and β-glucosidase
activities; 3) whether systemic estrogen levels were asso-
ciated with fecal estrogen levels (both deconjugated and
conjugated); and 4) whether fecal estrogen levels were
associated with fecal microbial diversity.Methods
The study design and analyses were consistent with the
Strengthening the Reporting of Observational studies in
Epidemiology – Molecular Epidemiology (STROBE-ME)
statement [20].Participants
Following review and approval of the protocol by the
National Cancer Institute (NCI) Special Studies Institu-
tional Review Board, healthy volunteer employees of the
NCI Division of Cancer Epidemiology and Genetics were
recruited to assess the reproducibility of microbial mea-
sures in self-collected fecal specimens and associations
with urine estrogens. Following face-to-face instructions
and informed consent, participants were provided a toilet-
attached pouch (Protocult, Rochester, MN), from which
they collected aliquots of an early or mid-morning stool,
as well as a simultaneous urine specimen. After specimen
collection, they completed a brief self-administered ques-
tionnaire on demographics, broad dietary categories, ease-
of-use of two different fecal collection devices, and factors
potentially related to gut microbiota, specifically age, sex,
height, waist size, current weight, weight change within 12
months, inflammatory bowel disease, gastrointestinal sur-
gery, cancer and other serious disease, food allergy, and
dietary restrictions (vegan or vegetarian, gluten, lactose,
peanuts, pork or shellfish) [16]. Postmenopausal women
were those over age 50 years with no menses, pregnancy
or childbirth within the previous 12 months. Premenopau-
sal women were those with menses, pregnancy or child-
birth within the previous 12 months. None of the women
had had a hysterectomy.
Urine specimens
Urine (20-50 mL) was collected in a screw-top sterile
container without preservative. Urine was chilled imme-
diately on frozen gel packs (4°C); frozen in liquid nitro-
gen within 3 hours; then thawed once to make 1ml
aliquots, which were re-frozen and kept at -80°C until
use for analysis of estrogens and estrogen metabolites.
Fecal specimens
Participants collected 16 aliquots, half in RNAlater
(QIAGEN Inc., Valencia, CA) and half in sterile phosphate
buffer saline (PBS), from various parts of a single stool. As
with the urine, all fecal aliquots were chilled immediately
on frozen gel packs (4°C) and frozen in liquid nitrogen
within 3 hours. The fecal aliquots were stored at -80°C
until used for DNA and protein extraction.
Protein extraction
Approximately 0.5gr of thawed feces was transferred
onto a 10 mL conical tube containing 5 mL of extraction
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KCl, 1 mM MgSO4) and kept on ice. Fecal material was
homogenized by heavy vortexing for 1 min and bacterial
cells were lysed by sonication using a Misonix XL2000
Ultrasonic Homogenizer (Fisher Scientific, Pittsburgh,
PA) at max power for three 30-second intervals on an
ice bath. Lysates were centrifuged at 21K ×g (15K rpm)
for 30 minutes at 4°C using an Eppendorf 5424 micro-
centrifuge. Supernatant containing extracted proteins
was transferred to new tubes and used to measure pro-
tein concentration and enzymatic activity. Protein con-
centration was estimated from each lysate using the
bicinchoninic acid method according to the manufac-
turer’s instructions (PIERCE, Rockford, IL).
Enzymatic activities
Protein extraction and enzymatic activities were per-
formed as described by Goldin and colleagues [21] with
slight modifications to optimize detection of the enzym-
atic activities. Activities of β-glucuronidase and β-
glucosidase (the control enzyme) were measured in a
96-microplate format using approximately 100mg of in-
put protein from fecal lysates (in 100 μL volume with
PBS). The final reaction volume was 200 μL/well, com-
posed of 100 μL sample and 100 μL of either 10 mM
4-Nitrophenyl-β-D-glucuronide pH7.0 (for β-glucuroni-
dase) or 10 mM 4-Nitrophenyl-β-D-glucopyranoside
pH7.0 (for β-glucosidase) preincubated at 37°C, which
was added immediately before starting the enzymatic
reaction. Enzymatic activity was measured in triplicates
by following real-time kinetics at 37°C of the product
4-nitrophenol. The increment of the product was moni-
tored at 405 nm for 60 minutes for fecal extracts with suf-
ficient protein concentration, or for 5 hours for diluted
fecal samples, on a Spectramax M5 (Molecular Devices,
Sunnyvale, CA). Enzymatic concentrations were deter-
mined from standards curves of pure enzymes from
Sigma-Aldrich (St. Louis MO, G7646 for β-glucuronidase,
G4511). This relates to β-glucosidase as controls and nor-
malized by protein input. Enzymatic activity was reported
as the mean value of triplicate runs in IU/100 mg protein.
Estrogens in urine and feces
Liquid chromatography/tandem mass spectrometry (LC-MS/
MS) was used to quantify estrogens in 1mL of urine and fecal
lysate in PBS [22,23]. Parent estrogens detected included
estrone and estradiol; estrogen metabolites (EM) included
estriol, 2-hydroxyestrone, 2-methoxyestrone, 2-hydroxyestra-
diol, 2-methoxyestradiol, 2-hydroxyestrone-3-methyl ether,
4-hydroxyestrone, 4-methoxyestrone, 4-methoxyestradiol,
16α-hydroxyestrone, 17-epiestriol, 16-ketoestradiol, and
16-epiestriol. A 500 μL aliquot of urine was used in the
processing including enzymatic hydrolysis with glucuroni-
dase/sulfatase-containing buffer, extraction, derivatization,and detection with stable isotope-labeled internal stan-
dards. Estrogens were quantified against calibration curves
with 1000-fold linear ranges. Each batch included masked
quality control samples and standards. Urine estrogens,
which were determined for all participants, were expressed
as pM/mg creatinine in urine, which was measured in the
same samples. Fecal estrogens per pg/100 μL fecal lysate
were likewise determined for 7 postmenopausal women
and 22 men. The 19 premenopausal women and 3 men
(selected at random) were excluded for cost considerations.
To estimate deconjugated versus conjugated estrogen
levels, LC-MS/MS on the fecal lysates was repeated with-
out enzymatic hydrolysis. Conjugated estrogen was the
level without hydrolysis, and deconjugated estrogen was
the level with hydrolysis minus the level without hydrolysis.
The current analysis considered estradiol, estrone, the EM
grouped into three major hydroxylation pathways (2-, 4-
and 16-hydroxylation), and the sum of these, designated as
total estrogens.
Fecal DNA extraction
Genomic DNA from stool samples preserved and trans-
ported in RNAlater was extracted with a modification of
the stool QIAamp DNA Stool mini kit (QIAGEN, Valencia,
CA). Briefly, 300 mg of stool sample were mixed with
350 μL of lysis buffer composed of 0.05 M potassium phos-
phate buffer containing 50 μL lyzosyme (10 mg/mL), 6 μL
of mutanolysin (25,000 U/ml; Sigma-Aldrich) and 3 μL of
lysostaphin (4 U/mL in sodium acetate; Sigma-Aldrich).
The mixture was incubated for 1 hour at 37°C then 10 μL
proteinase K (20 mg/ml), 100 μL 10% SDS, 20 μL RNase A
(20 mg/ml) were added, and the mixture was incubated for
1 hour at 55°C. Microbial cells were lysed by mechanical
disruption (bead beating) using a FastPrep instrument (MP
Biomedicals, Solon, OH) set at 6.0 m/s for 30 sec. The
lysate was processed using the ZR Fecal DNA extraction
kit (ZYMO Research, Irvine, CA) and according to the
manufacture’s recommendation omitting the lysis steps
(steps 1-3). The DNA was eluted into 100 μL of Tris EDTA
(TE) buffer, pH8.0.
454 Pyrosequencing of 16S rRNA genes
Universal primers 27F and 338R were used for PCR
amplification of the V1-V2 hypervariable regions of 16S
rRNA genes. The 338R primer included a unique se-




TAGGAGT-30, where the underlined sequences are the
454 Life SciencesW FLX sequencing primers B and A in
27F and 338R, respectively, and the bold font denotes
the universal 16S rRNA primers 27F and 338R. The 8bp
barcode within primer 338R is denoted by 8 Ns. Using
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genes were amplified in 96 well microtiter plates as follows:
5.0 μL 10X PCR buffer II (Applied Biosystems, Foster City,
CA), 3.0 μL MgCl2 (25 mM; Applied Biosystems), 2.5 μL
Triton X-100 (1%), 2.0 μL deoxyribonucleoside tripho-
sphates (10 mM), 1.0 μL each of primer 27F and 338R
(20 pmol/μL each), 0.5 μL AmpliTaq DNA polymerase
(5 U/μL; Applied Biosystems), and 50ng of template DNA
in a total reaction volume of 50 μL. Reactions were run in
a PTC-100 thermal controller (MJ Research Inc., Waltham,
MA) using the following cycling parameters: 5 minutes of
denaturation at 95°C, followed by 20 cycles of 30 seconds
at 95°C (denaturing), 30 seconds at 56°C (annealing) and
90 seconds at 72°C (elongation), with a final extension at
72°C for 7 minutes. Non-template controls were used as
negative controls for each set of barcoded primers. The
presence of amplicons was confirmed by gel electrophor-
esis on a 2% agarose gel and staining with SYBRGreen (Ap-
plied Biosystems, Foster City, CA). Equimolar amounts
(~100 ng) of the PCR amplicons were mixed in a single
tube, and amplification primers and reaction buffer were
removed by processing the mixture with the Agencourt
AMPure XP Kit (Beckman Coulter Genomics, Danvers,
MA). The purified amplicon mixtures were sequenced by
454 FLX Titanium pyrosequencing (Roche Diagnostics
Corp., Indianapolis, IN) with 454 Life SciencesW primer A
by the Genomics Resource Center at the Institute for Gen-
ome Sciences, University of Maryland School of Medicine
using protocols recommended by the manufacturer.
Classification of operational taxonomic units
Sequence read quality used the Institute of Genome
Sciences bioinformatics pipeline that complies with stand-
ard operating procedures of the National Institutes of
Health Human Microbiome Project [24]. Briefly, after
trimming the primer and barcode sequences, raw sequence
reads were filtered using the QIIME pipeline (http://qiime.
sourceforge.net) [25] with the following criteria to optimize
the quality and integrity of the data: 1) minimum and max-
imum read length of 300 bp and 500 bp; 2) no ambiguous
base calls; 3) no homopolymeric runs longer than 8 bp; 4)
average quality value >q25 within a sliding window of
50 bp; 5) 60% match to a previously determined 16S rRNA
gene sequence; and 6) chimera-free using the UCHIME
software (http://www.drive5.com/uchime/) [26]. Sequence
reads with the same barcode were binned by sample. Oper-
ational taxonomic units (OTUs) were defined using QIIME
as sequences with at least 97% identity, and sequences
were classified at the genus level using the Ribosomal
Database Project (RDP) naïve Bayesian classifier [27].
Statistical analysis
Relative abundance of each OTU, alpha diversity, and
beta diversity were computed using QIIME [25] for eachDNA sample and then averaged on four replicates for each
study participant. Alpha diversity was estimated by the
Shannon index, which adjusts the number of OTUs
detected for their relative abundance (proportions).
Shannon index is calculated as minus the sum over OTUs
of the proportion of a given OTU times the logarithm of
that proportion in each sample. Beta diversity, which is a
measure of separation of the phylogenetic structure of the
OTUs in one participant, compared to all other partici-
pants, was estimated by unweighted Unifrac distances
[25]. Taxa were classified by RDP with the Visualization
and Analysis of Microbial Population Structures (VAMPS,
Marine Biology Laboratories, Woods Hole, MA) pipeline.
Pearson correlations were computed for each loge estro-
gen level with each loge enzymatic activity level and with
each microbiome alpha diversity estimate. Two-sided
P-values were computed. For the 55 taxa with mean rela-
tive abundance of at least 0.1%, as well as the six phyla, or-
dinal levels were created [zero, low (below median of
detected sequences), high] and compared to loge β-
glucuronidase and log β-glucosidase enzymatic activity
levels by linear regression. Significance was based on two-
sided tests with α=0.05. Analyses were conducted using
the statistical software SAS version 9.2 (SAS Institute Inc,
Cary, NC) and R version 2.13.0 (http://www.r-project.org/).
Role of the funding source
This research was supported by the Intramural Research
Program of the NCI, NIH, which had no direct role in
the data analysis, manuscript preparation, or decision to
submit for publication.
Results
Urinary estrogens and estrogen metabolites by sex
and menopause status
We recruited 51 participants, including 25 men, 7 postme-
nopausal women, and 19 premenopausal women, who had
a mean age of 40 years (range 17-65) and did not differ sig-
nificantly by sex on responses on a questionnaire [16,17].
The premenopausal women included 4 in early follicular
phase, 7 in mid-follicular phase, 3 in luteal phase, and 5
undefined (e.g., lactating or on contraceptive medication).
The postmenopausal women ranged in age from 53 to 65
years. As reported previously [16], four participants were
vegetarian; none was vegan. Thirteen participants had
taken an antibiotic within six months of enrollment, in-
cluding three who had taken an antibiotic within one
month. A non-antibiotic prescription had been used within
one month of enrollment by 17 participants and 2-6
months before enrollment by 11 additional participants. As
expected [19,28-31], men and postmenopausal women had
similar estrogen and EM levels in urine (Figure 1 top, and
Table 1). In contrast, non-pregnant premenopausal women





























Figure 1 Estrogen and estrogen metabolite (EM) levels in urine by sex and menopause status (upper panel), and in feces by
conjugation status (lower panel). Total urine estrogens were measured in 25 men, 7 postmenopausal women, and 19 premenopausal women.
Fecal estrogens were measured in a combined group of 22 men and 7 postmenopausal women. Mean levels (±1 standard error) are presented.
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mean total urine estrogen levels (pM/mg creatinine) were
82.6 [standard error of the mean (SEM) 7.6] in men, 68.7
(9.4) in postmenopausal women, and 155.1 (34.7) in pre-
menopausal women (Figure 1 top, and Table 1).
Urinary non-ovarian estrogens and fecal microbial diversity
We focused primarily on men and postmenopausal
women, grouped together, to investigate the determinants
of estrogens that are primarily from non-ovarian sources.
Levels of such non-ovarian estrogens were strongly asso-
ciated with fecal microbiome richness and alpha diversity
in 16S rRNA-based operational taxonomic units, estimatedas observed species and the Shannon index, respectively
(Figure 2A,B and Table 1). Adjustment for body mass
index, age and sex had negligible effect on the associations
of non-ovarian estrogen levels with observed species
(Padj=0.002) and Shannon index (Padj=0.01). Non-ovarian
estrogens were similarly associated with other alpha diver-
sity indices (Additional file 1: Table S1). Correlations
tended to be similar in men and postmenopausal women
(Table 1) and for the individual estrogens and EM
(Additional file 2: Figure S1).
In the premenopausal women, estrogen levels had no
associations with fecal microbiome richness or alpha di-
versity (Figure 2C,D, Table 1, Additional file 3: Figure S2).
Table 1 Correlation of microbial β-glucuronidase, β-glucosidase, alpha diversity, and richness with urinary estrogens
and estrogen metabolites
Men Postmenopausal women Premenopausal women
Estrogen and estrogen metabolites (EM)* N=25 N=7 N=19
Total estrogens, mean (SE) 82.6 (7.6) 68.7 (9.4) 155.1 (34.7)
- β-glucuronidase correlation R=0.30 P=0.15 R=0.31 P=0.51 R=0.003 P=0.99
- β-glucosidase correlation R=0.13 P=0.52 R=-0.002 P=1.00 R=0.08 P=0.76
- Shannon index R=0.53 P=0.007 R=0.71 P=0.07 R=0.04 P=0.89
- Observed species R=0.59 P=0.002 R=0.79 P=0.04 R=0.12 P=0.63
Estrone, mean (SE) 15.4 (2.0) 12.1 (1.6) 39.9 (13.8)
- β-glucuronidase correlation R=0.45 P=0.03 R=0.27 P=0.56 R=0.03 P=0.89
- β-glucosidase correlation R=0.32 P=0.12 R=-0.13 P=0.79 R=0.06 P=0.81
- Shannon index R=0.35 P=0.08 R=0.74 P=0.06 R=0.005 P=0.98
- Observed species R=0.45 P=0.02 R=0.80 P=0.03 R=0.09 P=0.71
Estradiol, mean (SE) 3.8 (0.5) 1.7 (0.2) 8.4 (2.6)
- β-glucuronidase correlation R=0.35 P=0.08 R=0.72 P=0.07 R=-0.06 P=0.81
- β-glucosidase correlation R=0.29 P=0.17 R=0.46 P=0.30 R=-0.07 P=0.79
- Shannon index R=0.25 P=0.22 R=0.60 P=0.16 R=-0.01 P=0.96
- Observed species R=0.38 P=0.06 R=0.72 P=0.07 R=0.09 P=0.73
2-pathway EM, mean (SE) 22.2 (2.1) 17.9 (2.9) 38.6 (7.7)
- β-glucuronidase correlation R=0.17 P=0.42 R=0.13 P=0.79 R=0.008 P=0.98
- β-glucosidase correlation R=0.14 P=0.51 R=-0.11 P=0.82 R=0.07 P=0.78
- Shannon index R=0.58 P=0.004 R=0.47 P=0.29 R=0.01 P=0.96
- Observed species R=0.64 P=0.0005 R=0.60 P=0.15 R=0.10 P=0.68
4-pathway EM, mean (SE) 3.3 (0.3) 3.5 (0.6) 6.0 (1.3)
- β-glucuronidase correlation R=0.06 P=0.76 R=0.03 P=0.96 R=-0.15 P=0.54
- β-glucosidase correlation R=-0.03 P=0.87 R=-0.22 P=0.63 R=0.02 P=0.94
- Shannon index R=0.46 P=0.02 R=0.26 P=0.57 R=-0.04 P=0.89
- Observed species R=0.59 P=0.002 R=0.49 P=0.26 R=0.07 P=0.78
16-pathway EM, mean (SE) 37.9 (4.4) 33.5 (4.8) 62.1 (12.3)
- β-glucuronidase correlation R=0.22 P=0.30 R=0.41 P=0.36 R=-0.04 P=0.89
- β-glucosidase correlation R=0.02 P=0.92 R=0.10 P=0.84 R=0.11 P=0.65
- Shannon index R=0.43 P=0.04 R=0.82 P=0.03 R=0.06 P=0.82
- Observed species R=0.46 P=0.02 R=0.84 P=0.02 R=0.13 P=0.60
* Mean [standard error (SE)] levels of urinary estrogens and EM (grouped as 2-, 4-, or 16-pathway) in pM/mg creatinine, and loge-transformed for Pearson correlation
and microbiome diversity analyses. Loge-transformed fecal microbial enzyme activity (mean of triplicate measures in duplicate Sarstedt tubes) in IU/mg protein.
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were associated with beta diversity, which summarizes
pairwise differences between individuals (UniFrac metrics,
http://qiime.sourceforge.net) [32] (all P>0.20, Additional
file 4: Table S2).
Urinary non-ovarian estrogens and fecal microbial taxonomy
A few strains of bacteria have been reported to metabolize
estrogens and EM in vitro [33], but systemic estrogen levels
have not been linked to any particular organism. To ex-
plore possible taxonomic associations with estrogens, 16S
rRNA pyrosequences, assigned to phylogenetic taxa withthe naïve Bayesian Ribosomal Data Project (RDP) classifier
[27], were compared to urine estrogen and EM levels.
Estrogens were not associated with taxonomic relative
abundance at the phylum level. However, of 55 taxa at the
family and genus level with mean relative abundance
≥0.1%, non-ovarian urine estrogen levels were strongly and
significantly associated with Clostridia taxa in the Firmi-
cutes, including non-Clostridiales and three genera in the
family Ruminococcaceae (β=0.57 to 0.70, P=0.03 to 0.002,
Figure 3 and Table 2). These associations were primarily
driven by levels of estrone (Table 2). Levels in premeno-
pausal women were not associated with relative abundance
Figure 2 Correlations of total urine estrogen level with fecal microbiome richness (number of observed species) and alpha diversity
(Shannon index) in 25 men and 7 postmenopausal women (A,B) and in 19 premenopausal women (C,D).
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total premenopausal estrogens with abundance of non-
Clostridiales Firmicutes was almost nil (β=-0.10, P=0.55).
Urinary non-ovarian estrogens and fecal microbial enzymes
Intestinal contents can hydrolyze several estrogens and EM
[34]. These reactions have been attributed to gut luminal
bacteria, based largely on the effects of antibiotics on fecal
and systemic estrogen and EM levels [35]. With well vali-
dated assays on the fecal specimens from our male and
postmenopausal volunteers [17], fecal β-glucuronidase ac-
tivity was significantly correlated with urine estrone level
(R=0.36, P=0.04) but not with total urine estrogens
(R=0.24, P=0.19), estradiol (R=0.16, P=0.38), or EM. Activ-
ity of the control enzyme, β-glucosidase, was not related to
total urine estrogens (R=0.12) or to any of the parent estro-
gens or EM. In pre-menopausal women, urine estrogens
were not correlated with either β-glucuronidase or β-
glucosidase activity (Table 1).
Fecal estrogens, urinary estrogens, and fecal microbial
enzymes
As previously noted in a few individuals [28,34,35], in feces
we readily detected both conjugated and deconjugatedestrone, estradiol, estriol and 16-epiestriol (but not 11 other
EM) in all 29 participants examined (Figure 1 bottom).
Deconjugated fecal estrogens were inversely correlated with
total estrogen levels in urine (Figure 4A, R=-0.43, P=0.02),
and this inverse association with urine estrogens was espe-
cially strong for deconjugated fecal estrone (R=-0.50,
P=0.005, Table 3). Conjugated estrogens and EM in feces
were not significantly correlated with urinary estrogen
levels (Table 3). Fecal β-glucuronidase activity was inversely
correlated with both deconjugated and conjugated estro-
gens in feces (P≤0.01 for all except 16-epiestriol, Figure 4B).
Higher fecal microbiome Shannon index and number of
observed species were strongly and significantly associated
with lower levels of conjugated and especially deconjugated
estrogens in feces (Figure 4C,D and Table 3). The inverse
correlations imply that more estrogen is excreted through
feces when microbial diversity and enzymatic activity
are low.
Discussion
Our study supports, for the first time in a population of
human volunteers, the longstanding theory that the in-
testinal microbiota affects systemic estrogen levels
[9,11,28,35,36]. As postulated [11,28,35], we found that
Figure 3 Four Clostridia taxa of Firmicutes in feces significantly associated with total urine estrogens in 32 participants (25 men and 7
postmenopausal women). For each taxon, mean relative abundance (range 0.2% - 4.4%) and levels [none, low (below median), else high
relative abundance] are shown.
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enzyme, β-glucosidase) was inversely associated with all
estrogen levels in the gut, and directly associated with
estrone level in the urine. More importantly, we found
that the richness of the fecal microbiome (i.e., number
of unique species) was very strongly and directly asso-
ciated with systemic estrogens. These associations were
robust to different classifications of microbiome alpha
diversity, and they held for estrone, estradiol, and EM.
Our beta diversity analysis suggests that estrogen levels
are not associated with any particular class or cluster in
the microbiome. Rather, our findings point to relatively
rare taxa, particularly to certain Clostridia in the Firmi-
cutes phylum. Independent replication is required, asthese taxonomic associations were not specified a priori
and may have arisen by chance because of the many taxa
that were examined.
We confirmed previous reports that estrogen levels are
similar in men and postmenopausal women but substan-
tially lower and less variable than in premenopausal
women [19,28-31]. In premenopausal women, ovarian
estrogens dominate estrogens that are reabsorbed from the
gut. Thus, our null associations in premenopausal women
lend specificity to the conclusion that the intestinal micro-
biota affects non-ovarian systemic estrogen levels. A pos-
sible contribution of enterohepatic circulation to luteal
(nadir) estrogen levels in premenopausal women would re-
quire a specially designed and controlled investigation.
Table 2 Association of bacterial phyla and selected genera with urine estrogen levels in men and postmenopausal women*
Phyla, selected genera
(mean relative abundance)
Totalestrogens† Estrone† Estradiol† Estriol†
Beta† P-value Beta† P-value Beta† P-value Beta† P-value
Firmicutes (80.3%) 0.07 0.20 0.02 0.70 -0.0001 1.00 0.05 0.30
Firmicutes Clostridia
non-Clostridiales (0.2%) 0.70 0.004 0.61 0.01 0.55 0.004 0.49 0.02
Firmicutes Clostridia Clostridiales
Ruminococcaceae Oscillibacter (1.2%) 0.67 0.01 0.62 0.01 0.32 0.15 0.36 0.13
Ruminococcaceae Subdoligranulum (2.8%) 0.59 0.03 0.47 0.04 0.19 0.40 0.46 0.04
Ruminococcaceae genus NA (4.4%) 0.57 0.002 0.45 0.01 0.17 0.29 0.44 0.01
Bacteroidetes (16.9%) -0.07 0.19 -0.02 0.67 -0.01 0.88 -0.05 0.28
Actinobacteria (1.3%) 0.0004 0.41 -0.0003 0.93 0.001 0.72 0.005 0.21
Proteobacteria (0.5%) -0.24 0.27 -0.29 0.13 -0.28 0.10 -0.20 0.28
Fusobacteria (0.2%) -0.19 0.30 -0.15 0.34 -0.06 0.70 -0.22 0.15
Unclassified bacteria (0.8%) 0.39 0.11 0.33 0.12 0.21 0.29 0.28 0.18
* 25 men, 7 postmenopausal women. †Level (pM/mg creatinine) in urine. †Beta values estimate the increase in loge of estrogen per loge copy for phyla, else per
level (none, low, high) for genera and unclassified bacteria. P-values were not adjusted for multiple comparisons.
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http://www.translational-medicine.com/content/10/1/253The primary limitations of our study are its small size,
convenience sampling and cross-sectional design. These
limit the ability to detect associations and to generalize to
other populations. In addition, rather than studying a dis-
ease phenotype, we merely examined estrogen levels in aFigure 4 Correlations of fecal estrogen levels with urine estrogens (A
observed species and Shannon index (C,D) in 29 participants (7 postmrandom morning urine from volunteers who were highly
motivated and in good health. Nonetheless, given the pau-
city of understanding of the determinants of systemic estro-
gens and of the many functions of the gut microbiota and
its transient or sustained effects on the human host, our), fecal β-glucuronidase activity (B), and fecal microbiome
enopausal women and 22 men).
Table 3 Correlations of deconjugated and conjugated fecal estrogens and estrogen metabolites with total estrogen
levels in urine and with β-glucuronidase activity, observed species and Shannon index in feces in 29 participants
(7 postmenopausal women and 22 men)
Total urine estrogens Beta-glucuronidase Observed species Shannon index
Fecal estrogen R P-value R P-value R P-value R P-value
Total, deconjugated -0.43 0.02 -0.47 0.01 -0.66 0.0001 -0.58 0.001
Total, conjugated -0.23 0.22 -0.52 0.004 -0.52 0.004 -0.44 0.02
Estrone, deconjugated -0.50 0.005 -0.54 0.002 -0.66 0.00009 -0.59 0.0008
Estrone, conjugated -0.32 0.09 -0.48 0.008 -0.44 0.02 -0.36 0.05
Estradiol, deconjugated -0.28 0.15 -0.35 0.06 -0.65 0.0001 -0.62 0.0003
Estradiol, conjugated -0.11 0.55 -0.37 0.05 -0.37 0.05 -0.34 0.07
Estriol, deconjugated -0.41 0.03 -0.45 0.02 -0.55 0.002 -0.44 0.02
Estriol, conjugated -0.22 0.25 -0.47 0.01 -0.53 0.003 -0.44 0.02
16-Epiestriol, deconjugated -0.32 0.09 -0.28 0.15 -0.52 0.004 -0.43 0.02
16-Epistriol, conjugated -0.01 0.95 -0.30 0.12 -0.35 0.07 -0.29 0.14
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http://www.translational-medicine.com/content/10/1/253study is noteworthy for its finding that intestinal microbial
richness and certain taxa may contribute to systemic estro-
gen levels and associated diseases. Because use of medica-
tions, including non-antibiotics [16], and elevated BMI
[15,16] are inversely associated with gut microbiome alpha
diversity, adjustment for these likely would have strength-
ened the direct associations that we found herein between
alpha diversity and systemic estrogen levels. Finally, it
would be useful to identify associations of microbiome
parameters with better estimates of systemic estrogens,
such as in 24 hour urine and repeated serum specimens.
As postulated and summarized by others [11], our
results support the hypothesis that breast cancer risk in
postmenopausal women and hip fracture risk in both
postmenopausal women and elderly men is modulated by
decades-long differences in systemic estrogens attributable
to differences in the intestinal microbiota. If so, a desirable
goal would be to manipulate the microbiota or specific mi-
crobial functions to reduce disease risks. For example, in-
hibition of fecal microbial β-glucuronidases may be
possible [37], although the relatively weak associations that
we found between fecal β-glucuronidase activity and urin-
ary estrogens suggest that enzyme inhibition would not
markedly reduce systemic estrogen levels. For future work,
we would postulate that the gut microbiota may contrib-
ute to enterohepatic recycling via deconjugation of sul-
fated estrogens [38] or may mediate absorption of
estrogens via inflammation, neither of which was evalu-
ated herein. Validation of our findings in larger and more
representative populations, as well as much broader and
deeper understanding of how the gut contents and
mucosa modulate estrogen homeostasis, are needed.
Conclusions
Intestinal microbial richness and functions, including
but not limited to β-glucuronidase, influence levels ofnon-ovarian estrogens via enterohepatic circulation.
Thus, the gut microbial community may contribute to
the risk for estrogen-related conditions in older adults.
Understanding how Clostridia taxa relate to systemic
estrogens may identify targets for interventions.
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